A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma

Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐D...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Lihua, Si, Junqi, Kang, Junnan, Chen, Zehui, Nuermaimaiti, Rexidan, Qian, Zhengzi, Li, Lanfang, Zhou, Shiyong, You, Mingjian James, Zhang, Huilai, Tian, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575058/
https://www.ncbi.nlm.nih.gov/pubmed/36065965
http://dx.doi.org/10.1111/jcmm.17543
_version_ 1784811240731705344
author Qiu, Lihua
Si, Junqi
Kang, Junnan
Chen, Zehui
Nuermaimaiti, Rexidan
Qian, Zhengzi
Li, Lanfang
Zhou, Shiyong
You, Mingjian James
Zhang, Huilai
Tian, Chen
author_facet Qiu, Lihua
Si, Junqi
Kang, Junnan
Chen, Zehui
Nuermaimaiti, Rexidan
Qian, Zhengzi
Li, Lanfang
Zhou, Shiyong
You, Mingjian James
Zhang, Huilai
Tian, Chen
author_sort Qiu, Lihua
collection PubMed
description Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐DNA load in peripheral blood of all 26,527 patients with lymphoma, and the clinical characteristics and prognosis of 202 patients were retrospectively analysed, including 100 patients with positive EBV‐DNA and 102 randomly selected patients with negative EBV‐DNA. We found that the average rate of EBV‐DNA positivity in lymphomas was 0.376%, and EBV‐DNA‐positive patients presented higher risk with elevated lactate dehydrogenase (LDH) and β2‐MG level, B symptoms, secondary hemophagocytic syndrome and lower objective response rate compared to EBV‐DNA‐negative patients. Multivariate analysis revealed EBV‐DNA‐positive patients had inferior progression‐free survival (PFS) and overall survival (OS) and EBV‐DNA level before treatment was related to PFS but not OS of T/NK cell lymphoma. In T/NK cell lymphoma, EBV‐DNA converting negative after treatment was correlated with better PFS but not OS, and second‐line therapy could induce more EBV‐DNA‐negative conversion compared to CHOP‐based therapy. In all, EBV‐DNA positivity before treatment can be a biomarker representing the tumour burden and an independent prognostic factor. EBV‐DNA‐negative conversion after treatment is a good prognostic factor for T/NK cell lymphomas.
format Online
Article
Text
id pubmed-9575058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95750582022-10-17 A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma Qiu, Lihua Si, Junqi Kang, Junnan Chen, Zehui Nuermaimaiti, Rexidan Qian, Zhengzi Li, Lanfang Zhou, Shiyong You, Mingjian James Zhang, Huilai Tian, Chen J Cell Mol Med Original Articles Epstein–Barr virus (EBV) infection is proved to be associated with clinicopathology of lymphoma. However, little is known about the relationship between EBV‐DNA status after treatment and prognosis. In this study, real‐time polymerase chain reaction (PCR) was used for quantitative detection of EBV‐DNA load in peripheral blood of all 26,527 patients with lymphoma, and the clinical characteristics and prognosis of 202 patients were retrospectively analysed, including 100 patients with positive EBV‐DNA and 102 randomly selected patients with negative EBV‐DNA. We found that the average rate of EBV‐DNA positivity in lymphomas was 0.376%, and EBV‐DNA‐positive patients presented higher risk with elevated lactate dehydrogenase (LDH) and β2‐MG level, B symptoms, secondary hemophagocytic syndrome and lower objective response rate compared to EBV‐DNA‐negative patients. Multivariate analysis revealed EBV‐DNA‐positive patients had inferior progression‐free survival (PFS) and overall survival (OS) and EBV‐DNA level before treatment was related to PFS but not OS of T/NK cell lymphoma. In T/NK cell lymphoma, EBV‐DNA converting negative after treatment was correlated with better PFS but not OS, and second‐line therapy could induce more EBV‐DNA‐negative conversion compared to CHOP‐based therapy. In all, EBV‐DNA positivity before treatment can be a biomarker representing the tumour burden and an independent prognostic factor. EBV‐DNA‐negative conversion after treatment is a good prognostic factor for T/NK cell lymphomas. John Wiley and Sons Inc. 2022-09-06 2022-10 /pmc/articles/PMC9575058/ /pubmed/36065965 http://dx.doi.org/10.1111/jcmm.17543 Text en © 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Qiu, Lihua
Si, Junqi
Kang, Junnan
Chen, Zehui
Nuermaimaiti, Rexidan
Qian, Zhengzi
Li, Lanfang
Zhou, Shiyong
You, Mingjian James
Zhang, Huilai
Tian, Chen
A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
title A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
title_full A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
title_fullStr A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
title_full_unstemmed A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
title_short A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
title_sort retrospective analysis of ebv‐dna status with the prognosis of lymphoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575058/
https://www.ncbi.nlm.nih.gov/pubmed/36065965
http://dx.doi.org/10.1111/jcmm.17543
work_keys_str_mv AT qiulihua aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT sijunqi aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT kangjunnan aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT chenzehui aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT nuermaimaitirexidan aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT qianzhengzi aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT lilanfang aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT zhoushiyong aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT youmingjianjames aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT zhanghuilai aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT tianchen aretrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT qiulihua retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT sijunqi retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT kangjunnan retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT chenzehui retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT nuermaimaitirexidan retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT qianzhengzi retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT lilanfang retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT zhoushiyong retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT youmingjianjames retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT zhanghuilai retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma
AT tianchen retrospectiveanalysisofebvdnastatuswiththeprognosisoflymphoma